Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the North and East of France;Incidence et facteurs de risque de la séroconversion au virus de l'hépatite C dans une cohorte d'usagers de drogue intraveineux du nord-est de la France

Revue d'Epidemiologie et de Sante Publique

Volumn 54, Issue HS1, 2006, Pages

  Bruandet, A ^a   Lucidarme, D ^b   Decoster, A ^b   Ilef, D ^c   Harbonnier, J ^d   Jacob, C ^e   Delamare, C ^f   Cyran, C ^g   Van Hoenacker, A F ^h   Fremaux D ⁱ   Josse, P ^j   Emmanuelli, J ^a   Le Strat, Y ^a   Filoche, B ^b   Desenclos, J C ^a  

^a INSTITUT DE VEILLE SANITAIRE   (France)

^b GROUPE HOSPITALIER DE L'INSTITUT CATHOLIQUE DE LILLE   (France)

^c Cellule Interrégionale d'Epidemiologie de Nord Picardie   (France)

^d Centre Boris Vian   (France)

^e Centre Baudelaire   (France)

^f Centre Hospitalier de Thionville   (France)

^g Le Cèdre Bleu ^*  (France)

^h Le Cèdre Bleu   (France)

ⁱ Centre Drogue 80   (France)

^j Ufatt   (France)

more..

Author keywords

Hepatitis C; Prevention; Substitution

Indexed keywords

HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COTTON; COVARIANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPOSURE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; SYRINGE; TIME; VIRUS TRANSMISSION;

EID: 33746883141     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Dubois F, Desenclos JC, Mariotte N, Goudeau A. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology 1997; 25: 1490-6.
2. Pillonel J, Laperche S. Surveillance des marqueurs d'une infection par le VIH, l'HTLV et les virus des hépatites B et C chez les donneurs de sang en France. BEH 2001; 46: 207-9.
3. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-6.
4. Emmanuelli J, Jauffret M, Barin F. Épidémiologie du VHC chez les usagers de drogues, France, 1993-2002. BEH 2003; 16-17: 97-9.
5. Hernandez-Aguado I, Ramos-Rincon JM, Avinio MJ, Gonzalez-Aracil J, Perez-Hoyos S, de la Hera MG. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol 2001; 17: 539-44.
6. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149: 203-13.
7. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645-53.
8. Miller CL, Johnston C, Spitall PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737-42.
9. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-6.